Recently, the application of sodium-glucose cotransporter 2 (SGLT2) inhibitors, developed initially for treatment of type 2 diabetes mellitus, have shown major clinical benefits in all HF patients irrespective of diabetes status, including patients with HFpEF (16). Here, SLC5A2 is linked to type 2 diabetes mellitus.